Healis Therapeutics is developing a new class of neuromuscular therapeutics in psychiatry. Healis Co-Founder and CEO Dr. Eric Finzi first made headlines in 2006 when he published the first trial showing efficacy of botulinum toxin.Healis Therapeutics seeks to accelerate the development of botulinum toxin as a potential psychiatric treatment option for depression. Over 19 million Americans suffer from depression, with an estima...
Healis Therapeutics is developing a new class of neuromuscular therapeutics in psychiatry. Healis Co-Founder and CEO Dr. Eric Finzi first made headlines in 2006 when he published the first trial showing efficacy of botulinum toxin.Healis Therapeutics seeks to accelerate the development of botulinum toxin as a potential psychiatric treatment option for depression. Over 19 million Americans suffer from depression, with an estimated 280 million cases worldwide, according to the World Health Organization (WHO). By targeting different neuromuscular pathways than current treatments,
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.